Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASING
2024-517795-38-00Phase 2Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in hemangiopericytoma (HPC), sponsored by Italian Sarcoma Group. Primary endpoint: Overall tumor Response Rate (ORR) by RECIST v1.1. Started Jun 2019; status: completed.
02
Drugs
eribulin
03
Conditions
hemangiopericytoma (HPC)
Beyond the preview
Go deeper on 2024-517795-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517795-38-00.